Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sally Johnson

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Kidney International|May 11, 2020
Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathyVicky Brocklebank, Gurinder Kumar, Alexander J Howie, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 3, 2024
Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work GroupCarla Nester, Dima A Decker, Matthias Meier, et al.
Lancet (London, England)|March 16, 2024
Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohortKatie Wong, David Pitcher, Fiona Braddon, et al.
Kidney International Reports|July 31, 2024
Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases CohortKatie Wong, David Pitcher, Fiona Braddon, et al.
Kidney International|November 1, 2013
C3 glomerulopathy: consensus reportMatthew C Pickering, Vivette D D'Agati, Carla M Nester, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Kidney International|May 11, 2020
Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathyVicky Brocklebank, Gurinder Kumar, Alexander J Howie, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 3, 2024
Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work GroupCarla Nester, Dima A Decker, Matthias Meier, et al.
Lancet (London, England)|March 16, 2024
Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohortKatie Wong, David Pitcher, Fiona Braddon, et al.
Kidney International Reports|July 31, 2024
Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases CohortKatie Wong, David Pitcher, Fiona Braddon, et al.
Kidney International|November 1, 2013
C3 glomerulopathy: consensus reportMatthew C Pickering, Vivette D D'Agati, Carla M Nester, et al.
Pageof 5